Interleukin-1 beta (IL-1 beta)-converting enzyme cleaves the IL-1 beta precursor to mature IL-1 beta, an important mediator of inflammation. The identification of the enzyme as a unique cysteine protease and the design of potent peptide aldehyde inhibitors are described. Purification and cloning of the complementary DNA indicates that IL-1 beta-converting enzyme is composed of two nonidentical subunits that are derived from a single proenzyme, possibly by autoproteolysis. Selective inhibition of the enzyme in human blood monocytes blocks production of mature IL-1 beta, indicating that it is a potential therapeutic target.
Cysteine proteases related to mammalian interleukin-1 beta-converting enzyme (ICE) and the nematode cell death abnormal ced-3 gene product have been implicated in the effector mechanism of apoptotic cell death. Two novel members of this new family of ICE/CED-3-related proteases, designated ICErel-II and ICErel-III, were cloned from human monocytic cells. Both were highly homologous to human ICE (52% identical) and CED-3 (25% identical) and both contained the absolutely conserved pentapeptide sequence Gln-Ala-Cys-Arg-Asp containing the catalytic cysteine residue. Other structural motifs that were comparable with ICE suggest that ICErel-II and ICErel-III are also synthesized as larger proenzymes which are proteolytically processed to form heterodimeric active enzymes. Pro-interleukin-1 beta processing activity could not be detected in cells transfected with ICErel-II or ICErel-III, but pro-domain-less truncated forms of ICErel-II and ICErel-III were capable of effectively inducing fibroblast apoptosis. ICErel-II and ICErel-III may, therefore, participate in proteolytic events culminating in the apoptotic death of human cells.
Murine interleukin 1p (IL-10) convertase (mICE) was identified in cytosolic extracts of peritoneal exudate cells (PECs) and macrophage cell lines. mICE cleaves both the human and mouse IL-1lB precursors (pIL-l() at sites 1 and 2 but fails to cleave a human pIL-1p (Asp"" to Ala) mutant at site 2, indicating that Asp is required to the left of the scissile bond. Ac-Tyr-Val-Ala-Asp-amino-4-methyl coumarin, patterned after site 2 of human pIL-1(3, is a fluorogenic substrate for mICE, while the tetrapeptide aldehyde Ac-Tyr-Val-AlaAsp-CHO is a potent inhibitor (K, = 3 nM) that prevents generation and release of mature IL-11 by PECs (IC,5 = 7 pM). Cloning of a full-length 1.4-kb cDNA shows that mICE is encoded as a 402-aa proenzyme (p45) that can be divided into a prodomain (Met'-Asp'22), followed by a p20 subunit (Gly"AAsp296), a connecting peptide (Ser97-Asp3l4), and a plO subunit (Gly9'-His402). At the amino acid level, p45, p20, and plO are 62%, 60%, and 81% identical with human IL-13 convertase (hICE). The active site Cys284 lies within a completely conserved stretch of 18 residues; however, Ser2" in hICE, which aligns with the catalytic region of serine and viral cysteinyl proteases, is absent from mICE. Expression in Escherchia coli of a truncated cDNA encoding Asn"'-Hism generated active enzyme, which was autocatalytically processed at three internal Asp-Xaa bonds to generate a p20 subunit (Asn"'-Asp296) complexed with either pll (Ala-0"9-His42) or plO. Recombinant mICE cleaves murine pIL-1P accurately at the Asp"17-Val"'8 bond. The striking similarities of the human and murine enzymes will make it possible to assess the therapeutic potential of hICE inhibitors in murine models of disease.Interleukin 13 (IL-1p) is synthesized as a 31-kDa precursor polypeptide (pIL-108) that must be proteolytically cleaved to generate the active 17.5-kDa cytokine (1, 2). In stimulated human monocytes, processing requires a specific protease, termed IL-1p converting enzyme (ICE), which cleaves pIL-1,B at site 1 (Asp27-Gly28) and site 2 (Asp"16-Ala"7) to yield 28-and 17.5-kDa products, respectively (3). The recent purification and cloning of human ICE (hICE) (4,5) have revealed that the enzyme is a unique heterodimeric cysteine protease with a highly unusual requirement for Asp to the left of the scissile bond (P1). The active enzyme consists of a 1:1 stoichiometric complex of 19.8-(p20) and 10.2-(plO) kDa subunits, which are derived from a single 45.2-kDa (p45) proenzyme (4). In the proenzyme, Asp-Xaa bonds flank both subunits, as well as an alternatively processed form of p20, termed p24, suggesting that autoproteolysis may be involved in generating the heterodimeric (p20-plO) form of the enzyme (4).Inhibition of hICE prevents both cleavage of the IL-113 precursor and release ofthe mature cytokine from monocytes in lipopolysaccharide (LPS)-stimulated whole blood (4) and thus may represent a therapeutic approach for treating inflammatory diseases. To validate ICE as a therapeutic target, it will be necessary to establish ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.